NO20034300L - Nye cyano-substituerte dihydropyrimidinforbindelser og anvendelse for behandling av sykdommer - Google Patents
Nye cyano-substituerte dihydropyrimidinforbindelser og anvendelse for behandling av sykdommerInfo
- Publication number
- NO20034300L NO20034300L NO20034300A NO20034300A NO20034300L NO 20034300 L NO20034300 L NO 20034300L NO 20034300 A NO20034300 A NO 20034300A NO 20034300 A NO20034300 A NO 20034300A NO 20034300 L NO20034300 L NO 20034300L
- Authority
- NO
- Norway
- Prior art keywords
- diseases
- treatment
- dihydropyrimidine compounds
- substituted dihydropyrimidine
- new cyano
- Prior art date
Links
- -1 cyano-substituted dihydropyrimidine compounds Chemical class 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/20—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D239/22—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
- C07D211/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US27995601P | 2001-03-29 | 2001-03-29 | |
| PCT/US2002/009497 WO2002079149A2 (en) | 2001-03-29 | 2002-03-26 | Novel cyano-substituted dihydropyrimidine compounds and their use to treat diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20034300D0 NO20034300D0 (no) | 2003-09-26 |
| NO20034300L true NO20034300L (no) | 2003-11-07 |
Family
ID=23071059
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20034300A NO20034300L (no) | 2001-03-29 | 2003-09-26 | Nye cyano-substituerte dihydropyrimidinforbindelser og anvendelse for behandling av sykdommer |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US6809102B2 (pl) |
| EP (1) | EP1373221A4 (pl) |
| JP (1) | JP2005504725A (pl) |
| KR (1) | KR20030086327A (pl) |
| CN (1) | CN1507435A (pl) |
| AR (1) | AR034585A1 (pl) |
| BG (1) | BG108180A (pl) |
| BR (1) | BR0208405A (pl) |
| CA (1) | CA2442482A1 (pl) |
| CZ (1) | CZ20032645A3 (pl) |
| EE (1) | EE200300474A (pl) |
| HR (1) | HRP20030875A2 (pl) |
| HU (1) | HUP0400350A3 (pl) |
| IL (1) | IL157441A0 (pl) |
| IS (1) | IS6967A (pl) |
| MX (1) | MXPA03008634A (pl) |
| NO (1) | NO20034300L (pl) |
| PE (1) | PE20021013A1 (pl) |
| PL (1) | PL373759A1 (pl) |
| RU (1) | RU2003130961A (pl) |
| SK (1) | SK11062003A3 (pl) |
| TW (1) | TWI228416B (pl) |
| UY (1) | UY27232A1 (pl) |
| WO (1) | WO2002079149A2 (pl) |
| YU (1) | YU75803A (pl) |
| ZA (2) | ZA200306648B (pl) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6900214B2 (en) * | 2001-03-29 | 2005-05-31 | Bristol-Myers Squibb Company | Cyano-substituted dihydropyrimidine compounds and their use to treat diseases |
| WO2003051854A1 (fr) * | 2001-12-11 | 2003-06-26 | Kyowa Hakko Kogyo Co., Ltd. | Dérivé de thiadiazolines |
| NZ542227A (en) * | 2003-03-07 | 2008-12-24 | Astrazeneca Ab | Novel fused heterocycles and uses thereof |
| AR050920A1 (es) * | 2003-03-07 | 2006-12-06 | Astrazeneca Ab | Enantiomeros de heterociclos fusionados seleccionados y usos de los mismos |
| ES2377498T3 (es) * | 2003-04-18 | 2012-03-28 | Kyowa Hakko Kirin Co., Ltd. | Inhibidor de quinesina en etapa M |
| CA2528433A1 (en) * | 2003-06-10 | 2004-12-23 | Kyowa Hakko Kogyo Co., Ltd. | Thiadiazoline derivative |
| US7157461B2 (en) | 2003-07-23 | 2007-01-02 | Bristol-Myers Squibb Co. | Substituted dihydropyrimidine inhibitors of calcium channel function |
| US7166603B2 (en) | 2003-07-23 | 2007-01-23 | Bristol-Myers Squibb Co. | Dihydropyrimidone inhibitors of calcium channel function |
| WO2005037799A1 (en) * | 2003-10-16 | 2005-04-28 | Cytokinetics, Inc. | Compounds, compositions, and methods |
| WO2006008523A1 (en) * | 2004-07-22 | 2006-01-26 | Astrazeneca Ab | Fused pyrimidones usefuel in the treatment and the prevention of cancer |
| EP1781674A1 (en) * | 2004-08-18 | 2007-05-09 | AstraZeneca AB | Enantiomers of selected fused pyrimidones and uses in the treatment and prevention of cancer |
| US20060041128A1 (en) * | 2004-08-18 | 2006-02-23 | Astrazeneca Ab | Selected fused heterocyclics and uses thereof |
| WO2006060737A2 (en) * | 2004-12-03 | 2006-06-08 | Takeda San Diego, Inc. | Mitotic kinesin inhibitors |
| EP1870404A4 (en) * | 2005-03-22 | 2010-07-14 | Kyowa Hakko Kirin Co Ltd | MEANS FOR THE TREATMENT OF A HEMATOPOIETIC TUMOR |
| JP5060285B2 (ja) * | 2005-03-22 | 2012-10-31 | 協和発酵キリン株式会社 | 固形腫瘍治療剤 |
| EP1908755A4 (en) * | 2005-06-24 | 2009-06-24 | Kyowa Hakko Kirin Co Ltd | THERAPEUTIC AGENT AGAINST RESTENOSIS |
| DE102006002065B4 (de) * | 2006-01-16 | 2007-11-29 | Infineon Technologies Austria Ag | Kompensationsbauelement mit reduziertem und einstellbarem Einschaltwiderstand |
| CN110464722B (zh) * | 2019-06-06 | 2023-05-23 | 暨南大学 | 一类小分子化合物或其药学上可接受的盐在制备抗肿瘤转移药物中的应用 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6211198B1 (en) | 1993-04-05 | 2001-04-03 | Synaptic Pharmaceutical Corporation | Dihydropyridines and new uses thereof |
| MX9703518A (es) | 1994-11-16 | 1997-08-30 | Synaptic Pharma Corp | Dihidropirimidinas y usos de las mismas. |
| WO1997017969A1 (en) | 1995-11-16 | 1997-05-22 | Synaptic Pharmaceutical Corporation | Dihydropyrimidines and uses thereof |
| US6172066B1 (en) | 1996-05-16 | 2001-01-09 | Synaptic Pharmaceutical Corporation | Dihydropyrimidines and uses thereof |
| JP2000506904A (ja) | 1996-05-16 | 2000-06-06 | シナプティック・ファーマスーティカル・コーポレーション | ジヒドロピリミジン類およびその使用 |
| US6080760A (en) | 1997-06-18 | 2000-06-27 | Merck & Co., Inc. | Alpha 1A adrenergic receptor antagonists |
| WO1998057639A1 (en) | 1997-06-18 | 1998-12-23 | Merck & Co., Inc. | ALPHA 1aADRENERGIC RECEPTOR ANTAGONISTS |
| WO1999025345A1 (en) | 1997-11-14 | 1999-05-27 | Merck & Co., Inc. | Alpha-1a adrenergic receptor antagonists |
| AU768834B2 (en) | 1998-04-01 | 2004-01-08 | Yale University | A method for selectively modulating the interactions between survivin and tubulin |
| US6300084B1 (en) | 1998-10-08 | 2001-10-09 | The Regents Of The University Of California | Anti-mitotic agent screening process |
| AUPQ171999A0 (en) | 1999-07-20 | 1999-08-12 | University Of Sydney, The | Neurotropic virus transport |
| DE19935303A1 (de) | 1999-07-28 | 2001-02-08 | Aventis Pharma Gmbh | Oligonukleotide zur Inhibierung der Expression von humanem eg5 |
| CZ20021428A3 (cs) | 1999-10-27 | 2002-11-13 | Cytokinetics, Inc. | Způsoby a kompozice vyuľívající chinazoliny |
| US6617115B1 (en) | 1999-10-27 | 2003-09-09 | Cytokinetics, Inc. | Methods of screening for modulators of cell proliferation |
| US6284480B1 (en) | 2000-04-03 | 2001-09-04 | Cytokinetics, Inc. | Antifungal assay |
| US6900214B2 (en) | 2001-03-29 | 2005-05-31 | Bristol-Myers Squibb Company | Cyano-substituted dihydropyrimidine compounds and their use to treat diseases |
-
2002
- 2002-03-22 US US10/104,257 patent/US6809102B2/en not_active Expired - Lifetime
- 2002-03-25 TW TW091105771A patent/TWI228416B/zh not_active IP Right Cessation
- 2002-03-25 PE PE2002000232A patent/PE20021013A1/es not_active Application Discontinuation
- 2002-03-26 SK SK1106-2003A patent/SK11062003A3/sk unknown
- 2002-03-26 MX MXPA03008634A patent/MXPA03008634A/es unknown
- 2002-03-26 EE EEP200300474A patent/EE200300474A/xx unknown
- 2002-03-26 BR BR0208405-8A patent/BR0208405A/pt not_active IP Right Cessation
- 2002-03-26 EP EP02728592A patent/EP1373221A4/en not_active Withdrawn
- 2002-03-26 PL PL02373759A patent/PL373759A1/pl not_active Application Discontinuation
- 2002-03-26 IL IL15744102A patent/IL157441A0/xx unknown
- 2002-03-26 HU HU0400350A patent/HUP0400350A3/hu unknown
- 2002-03-26 CZ CZ20032645A patent/CZ20032645A3/cs unknown
- 2002-03-26 CN CNA028074556A patent/CN1507435A/zh active Pending
- 2002-03-26 YU YU75803A patent/YU75803A/sh unknown
- 2002-03-26 JP JP2002577776A patent/JP2005504725A/ja not_active Withdrawn
- 2002-03-26 RU RU2003130961/04A patent/RU2003130961A/ru not_active Application Discontinuation
- 2002-03-26 HR HR20030875A patent/HRP20030875A2/hr not_active Application Discontinuation
- 2002-03-26 CA CA002442482A patent/CA2442482A1/en not_active Abandoned
- 2002-03-26 WO PCT/US2002/009497 patent/WO2002079149A2/en not_active Ceased
- 2002-03-26 KR KR10-2003-7012604A patent/KR20030086327A/ko not_active Withdrawn
- 2002-03-27 UY UY27232A patent/UY27232A1/es not_active Application Discontinuation
- 2002-03-27 AR ARP020101168A patent/AR034585A1/es unknown
-
2003
- 2003-08-26 ZA ZA200306648A patent/ZA200306648B/en unknown
- 2003-09-17 BG BG108180A patent/BG108180A/xx unknown
- 2003-09-18 ZA ZA200307320A patent/ZA200307320B/en unknown
- 2003-09-24 IS IS6967A patent/IS6967A/is unknown
- 2003-09-26 NO NO20034300A patent/NO20034300L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| US20030008888A1 (en) | 2003-01-09 |
| HRP20030875A2 (en) | 2004-08-31 |
| CN1507435A (zh) | 2004-06-23 |
| CA2442482A1 (en) | 2002-10-10 |
| EE200300474A (et) | 2003-12-15 |
| SK11062003A3 (sk) | 2004-08-03 |
| HUP0400350A3 (en) | 2005-06-28 |
| KR20030086327A (ko) | 2003-11-07 |
| WO2002079149A2 (en) | 2002-10-10 |
| EP1373221A4 (en) | 2004-09-29 |
| IS6967A (is) | 2003-09-24 |
| WO2002079149A3 (en) | 2003-02-27 |
| BG108180A (en) | 2004-09-30 |
| ZA200307320B (en) | 2004-12-20 |
| BR0208405A (pt) | 2004-03-30 |
| NO20034300D0 (no) | 2003-09-26 |
| RU2003130961A (ru) | 2005-04-10 |
| EP1373221A2 (en) | 2004-01-02 |
| AR034585A1 (es) | 2004-03-03 |
| UY27232A1 (es) | 2002-11-29 |
| JP2005504725A (ja) | 2005-02-17 |
| MXPA03008634A (es) | 2003-12-08 |
| PL373759A1 (pl) | 2005-09-05 |
| HUP0400350A2 (hu) | 2005-01-28 |
| CZ20032645A3 (cs) | 2004-06-16 |
| IL157441A0 (en) | 2004-03-28 |
| YU75803A (sh) | 2006-05-25 |
| TWI228416B (en) | 2005-03-01 |
| US6809102B2 (en) | 2004-10-26 |
| ZA200306648B (en) | 2004-11-26 |
| PE20021013A1 (es) | 2002-11-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20034300L (no) | Nye cyano-substituerte dihydropyrimidinforbindelser og anvendelse for behandling av sykdommer | |
| DE60222671D1 (de) | Thienopyrimidinedione und deren verwendung in der behandlung von autoimmunerkrankungen | |
| EE200300485A (et) | Tiohüdantoinid ja nende kasutamine diabeedi raviks | |
| EE200300475A (et) | Türosiini kinaasi inhibiitorid, neid sisaldavad ravimkoostised ja nimetatud ühendid kasutamiseks haiguste ravis | |
| PL373333A1 (pl) | Stosowanie przeciwciał skierowanych przeciw TNFalfa i innego leku | |
| ATE389649T1 (de) | Substituierte amin-derivate und deren verwendung zur behandlung von angionese-bedingten erkrankungen | |
| NO20052894D0 (no) | 4-tetrazolyl-4-fenylpiperidin-derivater for behandling av smerte | |
| NO20043370L (no) | N-pyrazinylfenylsulfonamider og deres anvendelse ved behandling av kemokinmedierte sykdommer | |
| IS8135A (is) | Þríhringtengdar indólafleiður og notkun þeirra til að meðhöndla Alzheimers-sjúkdóm | |
| DE60209486D1 (de) | Pyranoindazole und ihre verwendung in der glaukombehandlung | |
| IS6966A (is) | Cýanó-tengd díhýdrópýrimídín efnasambönd og notkun þeirra við meðhöndlun sjúkdóma | |
| NO20041214L (no) | Substituerte benzimidazolforbindelser og deres anvendelse for behandling av cancer | |
| NO20031903L (no) | Nye amidoalkylpiperidin- og amidoalkylpiperazinderivater for anvendelse vedbehandling av nervesystemlidelser | |
| PL356784A1 (pl) | Substancja do zastosowania w leczeniu łuszczycy | |
| NO20041024D0 (no) | Anvendelse av BIBN4096 i kombinasjon med andre antimigrenelegemidler for behandling av migrene | |
| NO20053874D0 (no) | Formulering og metoder for behandling av thrombocytemi | |
| NO20035331D0 (no) | Nye heterocyklisk forbindelse og medisinsk anvendelse derav | |
| DK1496918T3 (da) | Anvendelse af natriummetaarsenit til behandling af tumorer | |
| NO20043029L (no) | Karboksamidinderivater og deres anvendelse ved behandling av vaskulaere sykdommer | |
| PT1381620E (pt) | Dissacaridos hipersulfatados e metodos de utilizacao dos mesmos para o tratamento de inflamacoes | |
| DK1461042T3 (da) | Anvendelse af desoxypeganin til behandling af klinisk depression | |
| AU2003244455A1 (en) | Piperidylcarboxamide derivatives and their use in the treatment of tachykinim-mediated diseases | |
| DK1680405T3 (da) | Bengamidderivater og deres anvendelse til behandling af kræftsygdomme | |
| IL163431A (en) | 1 - phenyl - 2 - heteroaryl - substituted benzimidazole derivatives and the use thereof for producing drugs used in the treatment of immunological diseases | |
| NO20033160D0 (no) | Anordning for behandling av gravann |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |